Literature DB >> 18245377

A causal role for ERG in neoplastic transformation of prostate epithelium.

Olga Klezovitch1, Michael Risk, Ilsa Coleman, Jared M Lucas, Manda Null, Lawrence D True, Peter S Nelson, Valeri Vasioukhin.   

Abstract

A significant proportion of human prostate cancers carry a chromosomal rearrangement resulting in the overexpression of the ETS transcription factor, ERG; however, the functional significance of this event is poorly understood. We report here that up-regulation of ERG transcript is sufficient for the initiation of prostate neoplasia. In agreement with measurements of ERG transcripts, we found that ERG protein is expressed in neoplastic human prostate epithelium. Overexpression of ERG in prostate cell lines increased cell invasion. Moreover, targeted expression of this transcript in vivo in luminal prostate epithelial cells of transgenic mice results in initiation of prostate neoplasia observed as the development of focal precancerous prostatic intraepithelial neoplasia (PIN). Similar to human cancers, luminal epithelial cells in these PIN lesions displace diminishing in numbers basal epithelial cells and establish direct contact with the stromal cell compartment. Loss of basal cells is considered to be one of the critical hallmarks of human prostate cancer; however, the mechanisms responsible for this event were unknown. We propose that up-regulation of ERG in human prostate cancer activates cell invasion programs that subsequently displace basal cells by neoplastic epithelium. Our data demonstrate that ERG plays an important causal role in the transformation of prostate epithelium and should be considered as a target for prevention or early therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245377      PMCID: PMC2538886          DOI: 10.1073/pnas.0711711105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

2.  The oncogenic TLS-ERG fusion protein exerts different effects in hematopoietic cells and fibroblasts.

Authors:  Junhui Zou; Hitoshi Ichikawa; Michael L Blackburn; Hsien-Ming Hu; Anna Zielinska-Kwiatkowska; Qi Mei; Gerald J Roth; Howard A Chansky; Liu Yang
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

3.  Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation.

Authors:  Shunyou Wang; Alejandro J Garcia; Michelle Wu; Devon A Lawson; Owen N Witte; Hong Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

4.  The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.

Authors:  Sotaro Miwa; Atsushi Mizokami; Evan T Keller; Russell Taichman; Jian Zhang; Mikio Namiki
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

5.  A molecular correlate to the Gleason grading system for prostate adenocarcinoma.

Authors:  Lawrence True; Ilsa Coleman; Sarah Hawley; Ching-Ying Huang; David Gifford; Roger Coleman; Tomasz M Beer; Edward Gelmann; Milton Datta; Elahe Mostaghel; Beatrice Knudsen; Paul Lange; Robert Vessella; Daniel Lin; Leroy Hood; Peter S Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-07       Impact factor: 11.205

6.  Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis.

Authors:  Daniel W Lin; Ilsa M Coleman; Sarah Hawley; Chung Y Huang; Ruth Dumpit; David Gifford; Philip Kezele; Hau Hung; Beatrice S Knudsen; Alan R Kristal; Peter S Nelson
Journal:  J Clin Oncol       Date:  2006-07-05       Impact factor: 44.544

7.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.

Authors:  Sven Perner; Francesca Demichelis; Rameen Beroukhim; Folke H Schmidt; Juan-Miguel Mosquera; Sunita Setlur; Joelle Tchinda; Scott A Tomlins; Matthias D Hofer; Kenneth G Pienta; Rainer Kuefer; Robert Vessella; Xiao-Wei Sun; Matthew Meyerson; Charles Lee; William R Sellers; Arul M Chinnaiyan; Mark A Rubin
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

8.  TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

Authors:  F Demichelis; K Fall; S Perner; O Andrén; F Schmidt; S R Setlur; Y Hoshida; J-M Mosquera; Y Pawitan; C Lee; H-O Adami; L A Mucci; P W Kantoff; S-O Andersson; A M Chinnaiyan; J-E Johansson; M A Rubin
Journal:  Oncogene       Date:  2007-01-22       Impact factor: 9.867

9.  TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.

Authors:  Kristiina Iljin; Maija Wolf; Henrik Edgren; Santosh Gupta; Sami Kilpinen; Rolf I Skotheim; Mari Peltola; Frank Smit; Gerald Verhaegh; Jack Schalken; Matthias Nees; Olli Kallioniemi
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

10.  TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.

Authors:  Sven Perner; Juan-Miguel Mosquera; Francesca Demichelis; Matthias D Hofer; Pamela L Paris; Jeff Simko; Colin Collins; Tarek A Bismar; Arul M Chinnaiyan; Angelo M De Marzo; Mark A Rubin
Journal:  Am J Surg Pathol       Date:  2007-06       Impact factor: 6.394

View more
  150 in total

Review 1.  Genomic rearrangements in prostate cancer.

Authors:  Christopher E Barbieri; Mark A Rubin
Journal:  Curr Opin Urol       Date:  2015-01       Impact factor: 2.309

2.  The oncogenic gene fusion TMPRSS2: ERG is not a diagnostic or prognostic marker for ovarian cancer.

Authors:  Lillian Huang; Isaiah G Schauer; Jing Zhang; Imelda Mercado-Uribe; Michael T Deavers; Jiaoti Huang; Jinsong Liu
Journal:  Int J Clin Exp Pathol       Date:  2011-09-15

3.  Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.

Authors:  Wendell S Fortson; Shubhalaxmi Kayarthodi; Yasuo Fujimura; Huali Xu; Roland Matthews; William E Grizzle; Veena N Rao; Ganapathy K Bhat; E Shyam P Reddy
Journal:  Int J Oncol       Date:  2011-04-21       Impact factor: 5.650

Review 4.  Novel therapies for the treatment of advanced prostate cancer.

Authors:  J M Clarke; A J Armstrong
Journal:  Curr Treat Options Oncol       Date:  2013-03

Review 5.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678

Review 6.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

7.  Chinese and Western prostate cancers show alternate pathogenetic pathways in association with ERG status.

Authors:  Liyan Xue; Xueying Mao; Guoping Ren; Elzbieta Stankiewicz; Sakunthala C Kudahetti; Dongmei Lin; Luis Beltran; Daniel M Berney; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

8.  ERG rearrangement metastasis patterns in locally advanced prostate cancer.

Authors:  Sven Perner; Maria A Svensson; Ruhella R Hossain; John R Day; Jack Groskopf; Ryan C Slaughter; Analee R Jarleborn; Matthias D Hofer; Rainer Kuefer; Francesca Demichelis; David S Rickman; Mark A Rubin
Journal:  Urology       Date:  2010-04       Impact factor: 2.649

Review 9.  Current mouse and cell models in prostate cancer research.

Authors:  Xinyu Wu; Shiaoching Gong; Pradip Roy-Burman; Peng Lee; Zoran Culig
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

Review 10.  Recurrent gene fusions in prostate cancer.

Authors:  Chandan Kumar-Sinha; Scott A Tomlins; Arul M Chinnaiyan
Journal:  Nat Rev Cancer       Date:  2008-06-19       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.